Elvina Almuradova· @Dr_ElvinaA · X·· 21 小时前评分70
正文 · 原文
HEALER: anbenitamab + HB1801 vs THP in HER2+ BC.
Median PFS: not reached vs 14.3 months
▪️HR 0.46 (95% CI 0.37–0.56)
24-month PFS: 58.5% vs 34.4%
An encouraging signal—longer follow-up and OS data will be key. #BCSM @myESMO @Larvol @KolPulseAI @OncoAlert #ESMO26
1 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com